ScienceAlert

Much-Hyped Alzheimer's Drugs Show No Meaningful Benefit, Major Review Finds

The Straits Times

Much-hyped Alzheimers drugs do not help patients, review finds

Guardian

Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes

BBC News

Breakthrough £90,000 Alzheimer's drugs unlikely to benefit patients, report suggests

Cochrane Library

Amyloid‐beta‐targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Independent

Alzheimer’s drugs ‘make no meaningful difference to patients,’ major study claims

The Pharmacist

Cochrane review finds anti-amyloid Alzheimer’s drugs show no 'clinically meaningful effect'

Science Media Centre

expert reaction to Cochrane review of anti-amyloid monoclonal antibodies for Alzheimers Disease

LinkedIn

Effect of gamechanger Alzheimers drugs trivial, review concludes Data assessed from 17 clinical trials of anti-amyloid drugs found no meaningful effect on cognitive decline Drugs that have

The New York Times

Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness

The Times

Verifying Device

The Australian

Bd3Cce0Ed89703F2F1852Aebec321632

Metaculus

Will a partial reprogramming-based therapy receive regulatory approval for treating Alzheimers disease before January 1, 2035?

A Cochrane review of 17 clinical trials involving more than 20,000 people found that anti-amyloid drugs for Alzheimer's disease had effects on cognitive decline and dementia severity that were "absent or trivial" and fell below thresholds for minimum clinically important difference.

A Cochrane review of 17 clinical trials involving more than 20,000 people found that anti-amyloid drugs for Alzheimer's disease had effects on cognitive decline and dementia severity that were "absent or trivial" and fell below thresholds for minimum clinically important difference.

The review examined seven anti-amyloid drugs, including lecanemab, sold as Leqembi by Biogen and Eisai, and donanemab, sold as Kisunla by Eli Lilly. Both drugs were approved by the U.S. and European Union but have been declined by state-run health services in the UK and France.

The review examined seven anti-amyloid drugs, including lecanemab, sold as Leqembi by Biogen and Eisai, and donanemab, sold as Kisunla by Eli Lilly. Both drugs were approved by the U.S. and European Union but have been declined by state-run health services in the UK and France.

The Cochrane review found that anti-amyloid drugs likely increase the risk of brain swelling and bleeding. Patients receiving the treatments must also visit a clinic every two to four weeks for intravenous infusions and regular MRI scans.

The Cochrane review found that anti-amyloid drugs likely increase the risk of brain swelling and bleeding. Patients receiving the treatments must also visit a clinic every two to four weeks for intravenous infusions and regular MRI scans.

Lead study author Francesco Nonino of Italy's IRCCS Institute said early trials showed statistically significant results but that it is "common for trials to find statistically significant results that do not translate into a meaningful clinical difference for patients."

Lead study author Francesco Nonino of Italy's IRCCS Institute said early trials showed statistically significant results but that it is "common for trials to find statistically significant results that do not translate into a meaningful clinical difference for patients."

Critics of the review, including Prof. Bart De Strooper of the UK Dementia Research Institute at UCL, argued the analysis "blurs" rather than clarifies evidence by combining older, failed drugs with newer treatments shown to deliver "modest yet real clinical benefit."

Daily Mail

Critics of the review, including Prof. Bart De Strooper of the UK Dementia Research Institute at UCL, argued the analysis "blurs" rather than clarifies evidence by combining older, failed drugs with newer treatments shown to deliver "modest yet real clinical benefit."

The Cochrane review's methodology involved pooling data across different anti-amyloid drugs on the basis that all share a similar mechanism of action by targeting amyloid-beta proteins. The most recent search date for included studies was Aug. 7, 2025.

The Cochrane review's methodology involved pooling data across different anti-amyloid drugs on the basis that all share a similar mechanism of action by targeting amyloid-beta proteins. The most recent search date for included studies was Aug. 7, 2025.

Alzheimer's Drugs Show 'Trivial' Benefits, Review Finds

Alzheimer's Drugs Show 'Trivial' Benefits, Review Finds

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Alzheimer's Drugs Show 'Trivial' Benefits, Review Finds

Alzheimer's Drugs Show 'Trivial' Benefits, Review Finds

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters